Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
The research suggests antibodies like these could be key ingredients in versatile lifesaving therapeutics capable of neutralizing all members of the Ebolavirus genus.
“This is like understanding how to kill five or six birds with one stone,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and senior author of the new papers, published recently in mBio and the Journal of Infectious Diseases. “The different viruses in the Ebolavirus genus vary in their structure, but all these different viruses have the same outbreak potential. We need a therapeutic approach that can target them all.”
A major challenge in treating what we call Ebola virus is that it isn’t just one pathogen but five. Members of the genus Ebolavirus include Ebola virus, Sudan virus, Bundibugyo virus, Taï Forest virus and Reston virus. Each of these viruses is up to 50 percent different in amino acid sequence, making it tough to develop broad treatment strategies. For example, the Sudan and Bundibugyo viruses were responsible for 40 percent of Ebola cases before 2013, yet current experimental Ebola therapies can’t neutralize them.
Adding to the threat, all members of the Ebolavirus genus could mutate to escape immune system defenses and fight off drug therapies.
The new research shows that antibodies that bind to a site on the viral “fusion loop” can neutralize all known ebolaviruses. The fusion loop is part of the machinery that the virus uses to fuse with human cells and initiate infection. Targeting this peptide could present an opportunity to develop a universal therapy for infections caused by all five members of the Ebolavirus genus.
For the mBio study, the researchers focused on a human antibody called ADI-15878. This antibody was found in the blood of an Ebola virus survivor and is the only human antibody ever found to neutralize all five members of the Ebolavirus genus.
So how does ADI-15878 do it?
Using a high-resolution structural technique called X-ray crystallography, the scientists modeled the interaction between the antibody and the viral glycoprotein (the protein that enables the virus to infect a cell). Ebola’s glycoprotein is covered with sugars that help to mask the virus from detection by the body’s immune system. The team observed that ADI-15878 binds directly to one of these sugars alongside a paddle-like structure on the fusion loop. Part of the antibody then dips down and binds into a pocket that is normally hidden by another part of the viral glycoprotein.
“It’s really cool to see that this antibody has found a way to bind into a cryptic, conserved pocket despite the proximity of sugars and other pieces of the virus that effectively hide this region from the immune system” says mBio study first author Brandyn West, PhD, a research associate at Scripps Research.
The researchers hypothesize that this action locks two important parts of Ebola’s fusion machinery together, making it impossible for the virus to get into human cells. The fusion loop is a key piece of the Ebola virus entry machinery, so its structure is what scientists refer to as highly conserved—meaning the virus can’t easily mutate the fusion loop to escape immune detection without compromising the ability of the virus to infect cells. If antibodies targeting this structure were included in therapies or elicited through vaccines, these antibodies should provide broad protection.
But was ADI-15878 just a one in a million antibody from a lucky human survivor?
The second paper the lab published this week in the Journal of Infectious Diseases shows that such antibodies are not out of reach. In this work, the scientists showed that a mouse which had been sequentially immunized with Ebola virus and then Sudan virus also had a broadly protective antibody response. The researchers demonstrate that an antibody, termed 6D6, from this mouse binds to the same region as ADI-15878. The immunization study provides more evidence that this part of the fusion loop is a promising target for vaccine design and therapies.
“Both the human and mouse antibodies were able to neutralize all known types of Ebola,” explains Jacob Milligan, PhD, research associate at Scripps Research and first author of the Journal of Infectious Diseases study.
It could be possible, the researchers say, for therapeutics to include antibodies that work like ADI-15878. Researchers working on Ebola vaccines could also design molecules that look like this region of the fusion loop. These molecules, called immunogens, teach the human immune system which piece of the virus to target.
“We’re hot on the trail of immunogen design strategies to produce more of these neutralizing antibodies,” Ollmann Saphire says.
The Latest on: Immunogens
via Google News
The Latest on: Immunogens
- Single-Cell Analysis Deepens Antibody Discoveryon February 1, 2020 at 4:26 am
When Briney and colleagues applied an iterative process of engineering and functional evaluation, they found, Briney recalled, immunogens that bind “orders of magnitude better than a native HIV ...
- Immunitor publishes interim results from Phase III trial of oral immunotherapy for liver canceron February 1, 2020 at 2:08 am
The US FDA granted Hepko-V5 orphan drug designation status in 2014. V5 inherently incorporates all circulating antigens from pooled blood of HCC patients, including tumor unrelated immunogens such as ...
- Salimetrics Launches New Salivary Human Total Immunoglobulin G (IgG) ELISA Kit to Support Multidisciplinary Investigators in Serological Studieson January 27, 2020 at 11:20 pm
Researchers will also be able to measure total IgG against any disease specific IgG assay targets to determine an individuals' exposure and immune response to specific immunogens. "The launch of ...
- GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccineon January 27, 2020 at 8:04 am
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infectious ...
- GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccineon January 27, 2020 at 7:38 am
On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine.
- Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencingon January 24, 2020 at 4:05 am
Finally, more studies will need to be done in order to characterize OmniRat serum and memory B cell responses to immunogens. Total RNA from spleens and lymph nodes was extracted (RNeasy Maxi Kit, ...
- HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entryon January 5, 2020 at 4:00 pm
HOOKIPA and Gilead Sciences designed and tested multiple arenaviral vectors expressing HIV and HBV immunogens, optimizing each for potential preclinical immunogenicity, safety and manufacturability.
- Ushering along B cells to neutralize HIVon December 5, 2019 at 10:59 am
On pages 1215 and 1216 of this issue, Saunders et al. (1) and Steichen et al. (2), respectively, use custom-designed HIV envelope (Env) proteins as immunogens in animal models to promote unusual ...
- Modified HIV immunogens engage neutralizing antibody precursorson January 20, 2019 at 4:00 pm
Unlike mature VRC01 antibodies, their inferred germline precursors are unable to bind and neutralize HIV, hindering experimental induction of effective bNAbs by HIV immunogens. The binding of germline ...
via Bing News